SCLX (Scilex Holding Co) Current Accrued Expense: $299.09 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
57 GF Score
Price $5.38
GF Value $6.33
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co Current Accrued Expense?

Scilex Holding Co SCLX +1.59% 57 Current Accrued Expense is $299.09 Mil as of Jun. 2026. GuruFocus rates SCLX with a GF Score™ of 57/100 and a GF Value™ of $6.33 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Scilex Holding Co's Current Accrued Expense for the quarter that ended in Jun. 2026 was $299.09 Mil.

Scilex Holding Co's quarterly Current Accrued Expense increased from Dec. 2025 ($301.39 Mil) to Mar. 2026 ($311.31 Mil) but then declined from Mar. 2026 ($311.31 Mil) to Jun. 2026 ($299.09 Mil).

Scilex Holding Co's annual Current Accrued Expense increased from Dec. 2023 ($98.30 Mil) to Dec. 2024 ($165.99 Mil) and increased from Dec. 2024 ($165.99 Mil) to Dec. 2025 ($301.39 Mil).

Scilex Holding Co Current Accrued Expense Related Terms

Scilex Holding Co Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Scilex Holding Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scilex Holding Co Current Accrued Expense Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 14.35 35.38 98.30 165.99 301.39

Scilex Holding Co Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 200.94 235.84 301.39 311.31 299.09
SCLX
57GF Score
Scilex Holding Co SCLX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scilex Holding Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $299.09 Mil mean?
Scilex Holding Co (SCLX) has a Current Accrued Expense of $299.09 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Scilex Holding Co and its competitors.
Is Scilex Holding Co's Current Accrued Expense too high?
Scilex Holding Co's current Current Accrued Expense is $299.09 Mil. Overall, Scilex Holding Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Current Accrued Expense compare to MIRA and NSRX?
Scilex Holding Co's Current Accrued Expense of $299.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Scilex Holding Co and its competitors. Scilex Holding Co's current Current Accrued Expense is $299.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.33, compared to a current price of $5.38 — trading 15% below its estimated fair value. The current Current Accrued Expense is $299.09 Mil. Scilex Holding Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Current Accrued Expense is $299.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be undervalued. The current stock price of $5.38 is trading 15% below its estimated GF Value™ of $6.33. GuruFocus considers Scilex Holding Co to be Modestly Undervalued.

Key valuation signals for SCLX:

  • Current Accrued Expense: $299.09 Mil
  • GF Value™: $6.33 vs. price of $5.38 (15% below fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
57GF Score

Get the complete analysis for SCLX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.38
Price
$6.33
GF Value